Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial

Autor: Krueger, James G., Ferris, Laura K., Menter, Alan, Wagner, Frank, White, Alexander, Visvanathan, Sudha, Lalovic, Bojan, Aslanyan, Stella, Wang, Elaine E.L., Hall, David, Solinger, Alan, Padula, Steven, Scholl, Paul
Zdroj: In The Journal of Allergy and Clinical Immunology July 2015 136(1):116-124
Databáze: ScienceDirect